Hip replacement patients may need less blood transfusions with right drug dose

NCT ID NCT03822793

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different doses of tranexamic acid, a drug that helps blood clot, to see which works best for reducing blood loss during hip replacement surgery. 170 patients were randomly assigned to receive either a placebo or one of three doses of the drug right at the start of surgery. The goal was to find the dose that minimizes hemoglobin drop and the need for blood transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tranexamic acid (Exacyl)
What this could lead to: If successful, this study could identify the best dose of tranexamic acid to reduce blood loss and transfusion needs during hip replacement surgery.
What could go wrong: This is a small, single-center phase 2 trial, so results may not apply to all patients. The optimal dose found here needs confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHROPATHY OF HIP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, hip

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHROPATHY OF HIP

Contacts and locations

Locations

CHU Saint-Etienne

Saint-Etienne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.